Abstract

IntroductionBone marrow-derived mesenchymal stem cells (BM-MSCs) for clinical use should not be grown in media containing fetal bovine serum (FBS), because of serum-related concerns over biosafety and batch-to-batch variability. Previously, we described the preparation and use of a cell-free native extracellular matrix (ECM) made by bone marrow cells (BM-ECM) which preserves stem cell properties and enhances proliferation. Here, we compare colony-forming ability and differentiation of MSCs cultured on BM-ECM with a commercially available matrix (CELLstart™) and tissue culture plastic (TCP) under serum-free conditions.MethodsPrimary MSCs from freshly isolated bone marrow-derived mononuclear cells or passaged MSCs (P1) were grown in serum-containing (SCM) or serum-free (SFM) media on BM-ECM, CELLstart™, or TCP substrates. Proliferation, cell composition (phenotype), colony-forming unit replication, and bone morphogenetic protein-2 (BMP-2) responsiveness were compared among cells maintained on the three substrates.ResultsProliferation of primary BM-MSCs was significantly higher in SCM than SFM, irrespectively of culture substrate, suggesting that the expansion of these cells requires SCM. In contrast, passaged cells cultured on BM-ECM or CELLstart™ in SFM proliferated to nearly the same extent as cells in SCM. However, morphologically, those on BM-ECM were smaller and more aligned, slender, and long.Cells grown for 7 days on BM-ECM in SFM were 20–40 % more positive for MSC surface markers than cells cultured on CELLstart™. Cells cultured on TCP contained the smallest number of cells positive for MSC markers. MSC colony-forming ability in SFM, as measured by CFU-fibroblasts, was increased 10-, 9-, and 2-fold when P1 cells were cultured on BM-ECM, CELLstart™, and TCP, respectively. Significantly, CFU-adipocyte and -osteoblast replication of cells grown on BM-ECM was dramatically increased over those on CELLstart™ (2X) and TCP (4-7X). BM-MSCs, cultured in SFM and treated with BMP-2, retained their differentiation capacity better on BM-ECM than on either of the other two substrates.ConclusionsOur findings indicate that BM-ECM provides a unique microenvironment that supports the colony-forming ability of MSCs in SFM and preserves their stem cell properties. The establishment of a robust culture system, combining native tissue-specific ECM and SFM, provides an avenue for preparing significant numbers of potent MSCs for cell-based therapies in patients.

Highlights

  • Bone marrow-derived mesenchymal stem cells (BM-Mesenchymal stem cell (MSC)) for clinical use should not be grown in media containing fetal bovine serum (FBS), because of serum-related concerns over biosafety and batch-to-batch variability

  • Our findings indicate that bone marrow extracellular matrix (BM-extracellular matrix (ECM)) provides a unique microenvironment that supports the colony-forming ability of MSCs in serum-free media (SFM) and preserves their stem cell properties

  • When freshly isolated primary human bone marrow mononuclear cells were cultured on tissue culture plastic (TCP), BM-ECM, or CELLstartTM, the number of cells after 2 weeks was significantly higher in serum-containing media (SCM) than SFM on all culture surfaces (Fig. 2), suggesting that expansion of primary human bone marrow cells requires SCM

Read more

Summary

Introduction

Bone marrow-derived mesenchymal stem cells (BM-MSCs) for clinical use should not be grown in media containing fetal bovine serum (FBS), because of serum-related concerns over biosafety and batch-to-batch variability. Throughout life, MSCs are continually involved in tissue regeneration and may be potentially useful as cell-based therapies for a number of diseases such as graft-versus-host disease, myocardial infarction, and diabetes (http://clinicaltrials.gov/). Because of their relative scarcity in adult bone marrow (approximately 0.001 %) [5, 6], MSCs must be expanded in vitro to obtain sufficient numbers for basic research studies or clinical applications. There are biosafety concerns, such as xenoimmunization and the risk of disease transmission by known or unknown pathogens (e.g., mycoplasma, viruses, and prions) [7,8,9]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call